This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drummond, D. C. Articles by Benz, C. C. Search for Related Content PubMed PubMed Citation Articles by Drummond, D. C. Articles by Benz, C. C.

Enhanced Pharmacodynamic and Antitumor Properties of a Histone Deacetylase Inhibitor Encapsulated in Liposomes or ErbB2-Targeted Immunoliposomes

Authors' Affiliations: ¹ Hermes Biosciences, Inc., South San Francisco, ² Buck Institute for Age Research, Novato, ³ University of California at San Francisco Comprehensive Cancer Center, San Francisco, California, and ⁴ First Affiliated Hospital of Jinan University, Guangzhou, P.R. China

Requests for reprints: Christopher C. Benz, Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945. Phone: 415-209-2092; Fax: 415-209-2232; E-mail: cbenz{at}buckinstitute.org.

ErbB2-overexpressing human cancers represent potentially sensitive targets for therapy by candidate histone deacetylase (HDAC) inhibitors as we have shown that HDAC inhibitors can selectively reduce ErbB2 expression by repressing the ErbB2 promoter and accelerating the decay of cytoplasmic ErbB2 transcripts. To extend these in vitro findings and enhance the in vivo pharmacodynamic properties of HDAC inhibitors, we stably encapsulated a potent hydroxamate-based HDAC inhibitor (LAQ824) within long-circulating liposomes (Ls-LAQ824) and immunoliposomes (ILs-LAQ824) bearing >10,000 LAQ824 molecules per nanovesicle. Liposomal LAQ824 exhibits prolonged in vivo stability and, unlike free LAQ824, circulates with a half-life of 10.8 hours following a single i.v. injection. Three weekly i.v. injections of 20 to 25 mg/kg Ls-LAQ824 in nude mice with ErbB2 overexpressing BT-474 breast tumor xenografts significantly impairs tumor growth, and administration of ErbB2-targeted ILs-LAQ824 may further improve this antitumor activity. Studies of tumor-bearing mice 24 hours after single treatment indicate that: (a) >10% of injected liposomal LAQ824 is still circulating (whereas free LAQ824 is undetectable in the blood after 15 minutes); and (b) tumor uptake of Ls-LAQ824 and ILs-LAQ824 is >3% injected drug per gram of tumor, producing levels of acetylated tumor histones that are 5- to 10-fold increased over those following free LAQ824 or saline treatments and resulting in concordantly reduced levels of tumor ErbB2 mRNA. These preclinical results support the clinical evaluation of HDAC inhibitors against ErbB2-overexpressing malignancies, and further indicate that encapsulation into targeted and nontargeted liposomes substantially improves the in vivo pharmacokinetics, tumor uptake, and antitumor properties of hydroxamate-based HDAC inhibitors.

Key Words: Liposomes • Histone deacetylase inhibitors • LAQ824 • Hydroxamate • HDAC • Immunoliposomes • Targeted drug delivery

This article has been cited by other articles:

				R. L. Piekarz and S. E. Bates Epigenetic Modifiers: Basic Understanding and Clinical Development Clin. Cancer Res., June 15, 2009; 15(12): 3918 - 3926. [Abstract] [Full Text] [PDF]

				D. C. Drummond, C. O. Noble, Z. Guo, M. E. Hayes, J. W. Park, C.-J. Ou, Y.-L. Tseng, K. Hong, and D. B. Kirpotin Improved Pharmacokinetics and Efficacy of a Highly Stable Nanoliposomal Vinorelbine J. Pharmacol. Exp. Ther., January 1, 2009; 328(1): 321 - 330. [Abstract] [Full Text] [PDF]

				G. K. Scott, C. Marx, C. E. Berger, L. R. Saunders, E. Verdin, S. Schafer, M. Jung, and C. C. Benz Destabilization of ERBB2 Transcripts by Targeting 3' Untranslated Region Messenger RNA Associated HuR and Histone Deacetylase-6 Mol. Cancer Res., July 1, 2008; 6(7): 1250 - 1258. [Abstract] [Full Text] [PDF]

				S. M. K. Pulukuri, B. Gorantla, and J. S. Rao Inhibition of Histone Deacetylase Activity Promotes Invasion of Human Cancer Cells through Activation of Urokinase Plasminogen Activator J. Biol. Chem., December 7, 2007; 282(49): 35594 - 35603. [Abstract] [Full Text] [PDF]

				M. T. Krauze, C. O. Noble, T. Kawaguchi, D. Drummond, D. B. Kirpotin, Y. Yamashita, E. Kullberg, J. Forsayeth, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of nanoliposomal CPT-11 (irinotecan) and PEGylated liposomal doxorubicin (Doxil) in rodent intracranial brain tumor xenografts Neuro-oncol, October 1, 2007; 9(4): 393 - 403. [Abstract] [Full Text] [PDF]

				D. P. Stiehl, D. M. Fath, D. Liang, Y. Jiang, and N. Sang Histone Deacetylase Inhibitors Synergize p300 Autoacetylation that Regulates Its Transactivation Activity and Complex Formation Cancer Res., March 1, 2007; 67(5): 2256 - 2264. [Abstract] [Full Text] [PDF]

				Y. Yamashita, M. T. Krauze, T. Kawaguchi, C. O. noble, D. C. Drummond, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts Neuro-oncol, January 1, 2007; 9(1): 20 - 28. [Abstract] [Full Text] [PDF]

				R. Saito, M. T. Krauze, C. O. Noble, D. C. Drummond, D. B. Kirpotin, M. S. Berger, J. W. Park, and K. S. Bankiewicz Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model Neuro-oncol, July 1, 2006; 8(3): 205 - 214. [Abstract] [Full Text] [PDF]

				J. J. Buggy, Z. A. Cao, K. E. Bass, E. Verner, S. Balasubramanian, L. Liu, B. E. Schultz, P. R. Young, and S. A. Dalrymple CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo Mol. Cancer Ther., May 1, 2006; 5(5): 1309 - 1317. [Abstract] [Full Text] [PDF]

				D. C. Drummond, C. O. Noble, Z. Guo, K. Hong, J. W. Park, and D. B. Kirpotin Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res., March 15, 2006; 66(6): 3271 - 3277. [Abstract] [Full Text] [PDF]

				C. O. Noble, M. T. Krauze, D. C. Drummond, Y. Yamashita, R. Saito, M. S. Berger, D. B. Kirpotin, K. S. Bankiewicz, and J. W. Park Novel Nanoliposomal CPT-11 Infused by Convection-Enhanced Delivery in Intracranial Tumors: Pharmacology and Efficacy. Cancer Res., March 1, 2006; 66(5): 2801 - 2806. [Abstract] [Full Text] [PDF]